ILC Therapeutics
Pioneering a new class of hybrid interferons to create life-transforming therapeutics
ILC Therapeutics (ILCT) is a Scottishbased biotechnology company and pioneer in the discovery and development of a ground-breaking new class of hybrid interferon drugs.
"We are living through the most rapidly evolving viral environment the world has seen. Catalysed by the global COVID crisis, governments and markets alike are recognising the critical need for effective and safe antiviral medicines, both to meet the immediate challenges of today and the inevitable new threats.
"ILC Therapeutics' 'hybrid interferon platform technology is well positioned to address these needs and Alfacyte™, our lead candidate, has the potential to become an important antiviral treatment in the ongoing global fight against COVID-19, RSV and other virus and future pandemic threats."
CEO Dr Alan Walker